[Vaccination against HPV in adults].
Gil
Ángel
Á
Departamento de Medicina Preventiva y Salud Pública, Facultad de Ciencias de Salud, Universidad Rey Juan Carlos, Spain.
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D002648:Child; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D052140:Human papillomavirus 11 / Q000276:immunology; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D052163:Human papillomavirus 6 / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000276:immunology* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D013030:Spain / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control; D014611:Vaccination; D058425:Vaccines, Virus-Like Particle / Q000276:immunology; D055815:Young Adult
D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines; D058425:Vaccines, Virus-Like Particle